Effect of different doses of nasal salmon calcitonin on bone mass

Abstract

Forty postmenopausal women with a former Colles' fracture were enrolled in a 1-year study to determine the dose-effect relationship of nasal salmon calcitonin (SCT) on bone mass. They were randomized to receive either placebo, 50, 100, or 200 IU per day of SCT given as a nasal spray. The rate of change in the bone mineral content of the lumbar spine was 0.7, 0.2, 1.1, and 2.0 gHA per year, respectively, and the rate of change in the bone mineral content in the forearm was -0.4, -0.1, 0.0, and -0.1 AU per year, respectively. The rate of change in the bone mineral content of the lumbar spine in patients receiving 200 IU of SCT per day differed significantly from zero (P less than 0.01). Except for one patient, who experienced intolerable nausea, no systemic side effects were observed. Seven patients withdrew, two patients from nasal intolerance to the spray. These preliminary data suggest that SCT given by the nasal route has a positive and dose-dependent effect on spinal bone mass, but affects forearm bone mass only minimally.

A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin

“…24 In smaller doses of 100 IU daily intranasally, calcitonin was less effective than 25 hydroxycholecalciferol in preventing bone loss in cardiac transplant recipients but there was no untreated control group in the study. 25 On an average of 17 months after liver transplantation 40 patients were enrolled to receive either calcitonin 40 IU daily intramuscularly or sodium etidronate 400 mg orally for 15 days every 3 months for 1 year.…”

A Randomized Trial of Nasal Spray Salmon Calcitonin in Men With Idiopathic Osteoporosis: Effects on Bone Mineral Density and Bone Markers

“…Several studies have shown its efficacy in the prevention of postmenopausal bone loss and in women with established osteoporosis. (13)(14)(15)(16)(17) Moreover, in one recent large study, nasal SCT (200 IU daily) reduced the rate of new vertebral fractures by 37% in postmenopausal women with osteoporosis. …”

Importance of Preclinical Studies in the Development of Drugs for Treatment of Osteoporosis: A Review Related to the 1998 WHO Guidelines

“…Thus, the slight increase in bone mass after initiation of estrogen therapy [26][27][28][29] or calcitonin [30][31][32] observed in postmenopausal women has been very well documented in aged ovariectomized rats [24,33]. Selective estrogen receptor modulators (SERM) such as tomoxifen, raloxifen or droloxifen have been shown to reduce bone turnover and bone loss in animal models of postmenopausal osteoporosis [34][35][36][37][38][39][40][41].…”